XYF-902

N/A

Report date: 2022/01/05 15:24:33

Base Information

Drug NameXYF-902

Drug Alias NameXYF-902

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsMitogen-activated protein kinase kinase kinase kinase 1B-lymphocyte antigen CD19CD22 +[4]

Therapy Area/IndicationsLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesXi'An Yufan Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesXi'An Yufan Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A